Family and Personal History of Malignancy in Intraductal Papillary Mucinous Neoplasm (IPMN)
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer, Pancreatic Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 85 |
| Updated: | 2/10/2018 |
| Start Date: | November 17, 2008 |
| End Date: | July 2020 |
| Contact: | Wendy K Chung, MD |
| Email: | wkc15@columbia.edu |
Family and Personal History of Pancreatic and Other Malignancies in Patients With Intraductal Papillary Mucinous Neoplasms
This is a retrospective observational study to determine the proportion of patients with a
family history of pancreatic cancer and other malignancies among patients who have
intraductal papillary mucinous neoplasm (IPMN).
The investigators will be reviewing the demographic, clinical, radiologic, pathologic, and
follow-up information from the Pancres Center database. The investigators will also conduct a
chart review to collect information recorded by clinicians on each subject's family history
of malignancy and personal history of malignancy. Results of this database and chart review
will be incorporated into a datasheet in which all patient identifiers have been removed.
The primary outcome will be the percentage of IPMN patients with at least one first-degree
relative with pancreatic cancer or IPMN, or at least two first or second degree relatives
with pancreatic cancer, IPMN, or malignancies related to pancreatic cancer syndromes,
including colorectal, gastric, breast, ovarian, and melanoma neoplasms. Secondary outcomes
will be the relative risk of IPMN subtypes of higher malignant potential (main duct or mixed
type location), more advanced histology (carcinoma in situ or invasive carcinoma), and
recurrence following surgical resection amongst subjects with a family history.
family history of pancreatic cancer and other malignancies among patients who have
intraductal papillary mucinous neoplasm (IPMN).
The investigators will be reviewing the demographic, clinical, radiologic, pathologic, and
follow-up information from the Pancres Center database. The investigators will also conduct a
chart review to collect information recorded by clinicians on each subject's family history
of malignancy and personal history of malignancy. Results of this database and chart review
will be incorporated into a datasheet in which all patient identifiers have been removed.
The primary outcome will be the percentage of IPMN patients with at least one first-degree
relative with pancreatic cancer or IPMN, or at least two first or second degree relatives
with pancreatic cancer, IPMN, or malignancies related to pancreatic cancer syndromes,
including colorectal, gastric, breast, ovarian, and melanoma neoplasms. Secondary outcomes
will be the relative risk of IPMN subtypes of higher malignant potential (main duct or mixed
type location), more advanced histology (carcinoma in situ or invasive carcinoma), and
recurrence following surgical resection amongst subjects with a family history.
Intraductal papillary mucinous neoplasm (IPMN) is a cyst-like cancer of the pancreas that is
increasingly being identified in medical practice, including during the screening of
individuals at high risk of pancreatic cancer. It has been established that 10 to 20% of
pancreatic cancers are familial. In comparison, there has been little research into the
importance of genetic risk in IPMN incidence. The investigators will perform a retrospective
chart review of patients with IPMN who were evaluated for surgical intervention at our
tertiary referral center. The investigators are interested in determining the proportion of
IPMN patients with a family history of pancreatic and other cancers. In addition, the
investigators will assess if familial cancer risk is associated with increased risk for
malignant IPMN and recurrence, relative to those patients without an inherited
predisposition.
increasingly being identified in medical practice, including during the screening of
individuals at high risk of pancreatic cancer. It has been established that 10 to 20% of
pancreatic cancers are familial. In comparison, there has been little research into the
importance of genetic risk in IPMN incidence. The investigators will perform a retrospective
chart review of patients with IPMN who were evaluated for surgical intervention at our
tertiary referral center. The investigators are interested in determining the proportion of
IPMN patients with a family history of pancreatic and other cancers. In addition, the
investigators will assess if familial cancer risk is associated with increased risk for
malignant IPMN and recurrence, relative to those patients without an inherited
predisposition.
Inclusion Criteria:
- Tissue-confirmed diagnosis of intraductal papillary mucinous neoplasm or imaging
suspicious for IPMN
- Seen in consultation for IPMN at Columbia-Presbyterian Medical Center between 2002 and
2008
Exclusion Criteria:
- Not meeting the inclusion criteria.
We found this trial at
1
site
630 W 168th St
New York, New York
New York, New York
212-305-2862
Principal Investigator: Wendy K Chung, MD
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
Click here to add this to my saved trials
